^
    1m
    A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=216, Active, not recruiting, Akeso | Trial primary completion date: Jul 2025 --> Apr 2026 | Not yet recruiting --> Active, not recruiting
    Enrollment closed • Trial primary completion date
    |
    Yidafan (ivonescimab) • lancastotug (AK127)
    1m
    A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC) (clinicaltrials.gov)
    P1/2, N=280, Recruiting, Akeso | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Avastin (bevacizumab) • Tyvyt (sintilimab) • Kaitanni (cadonilimab) • Yidafan (ivonescimab) • lancastotug (AK127)
    4ms
    A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours (clinicaltrials.gov)
    P1, N=67, Completed, Akesobio Australia Pty Ltd | Active, not recruiting --> Completed
    Trial completion
    |
    Kaitanni (cadonilimab) • lancastotug (AK127)
    1year
    A Phase Ia/Ib Open Label，Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 in Patients With Advanced Malignant Tumors (clinicaltrials.gov)
    P1, N=205, Recruiting, Akeso | Phase classification: P1a/1b --> P1
    Phase classification
    |
    Kaitanni (cadonilimab) • lancastotug (AK127)
    over1year
    A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours (clinicaltrials.gov)
    P1, N=66, Active, not recruiting, Akesobio Australia Pty Ltd | Recruiting --> Active, not recruiting | N=143 --> 66 | Trial primary completion date: Jan 2025 --> Oct 2024
    Enrollment closed • Enrollment change • Trial primary completion date • Combination therapy • Metastases
    |
    Kaitanni (cadonilimab) • lancastotug (AK127)
    over1year
    A Phase Ib/II Study of AK112 (PD-1/VEGF Bispecific Antibody) in Combination Therapy for Patients With Advanced Hepatocellular Carcinoma (HCC). (clinicaltrials.gov)
    P1/2, N=280, Not yet recruiting, Akeso
    New P1/2 trial • Combination therapy • Metastases
    |
    Avastin (bevacizumab) • Tyvyt (sintilimab) • Kaitanni (cadonilimab) • Yidafan (ivonescimab) • lancastotug (AK127)
    2years
    A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours (clinicaltrials.gov)
    P1, N=143, Recruiting, Akesobio Australia Pty Ltd | Phase classification: P1a/1b --> P1
    Phase classification • Combination therapy • Metastases
    |
    Kaitanni (cadonilimab) • lancastotug (AK127)
    over2years
    A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=216, Not yet recruiting, Akeso
    New P1/2 trial
    |
    Yidafan (ivonescimab) • lancastotug (AK127)
    almost3years
    A Study of AK127 Combined With AK104 in Patients With Advanced Malignant Tumors (clinicaltrials.gov)
    P1a/1b, N=205, Not yet recruiting, Akeso
    New P1 trial • Combination therapy • Metastases
    |
    Kaitanni (cadonilimab) • lancastotug (AK127)